Vetr lowered shares of Cempra Inc (NASDAQ:CEMP) from a buy rating to a sell rating in a research note issued to investors on Monday morning. The brokerage currently has $4.07 target price on the stock.
Several other research firms have also recently weighed in on CEMP. Morgan Stanley upgraded shares of Cempra from an underweight rating to an equal weight rating and set a $5.00 price target on the stock in a report on Friday, December 30th. Stifel Nicolaus restated a hold rating and set a $4.00 price target on shares of Cempra in a report on Wednesday, March 1st. Gabelli cut shares of Cempra from a buy rating to a hold rating in a report on Wednesday, November 23rd. Zacks Investment Research cut shares of Cempra from a buy rating to a hold rating in a report on Tuesday, February 28th. Finally, WBB Securities cut shares of Cempra from a buy rating to a hold rating and cut their price target for the stock from $40.00 to $4.00 in a report on Thursday, December 29th. Five research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have given a buy rating to the company’s stock. Cempra currently has an average rating of Hold and a consensus price target of $11.88.
Cempra (NASDAQ:CEMP) opened at 3.85 on Monday. Cempra has a 52 week low of $2.55 and a 52 week high of $26.95. The company has a 50-day moving average of $3.55 and a 200-day moving average of $10.17. The firm’s market capitalization is $201.71 million.
Cempra (NASDAQ:CEMP) last released its quarterly earnings results on Tuesday, February 28th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.03. Cempra had a negative return on equity of 59.94% and a negative net margin of 678.72%. The firm had revenue of $7.95 million for the quarter, compared to analysts’ expectations of $4.19 million. During the same quarter last year, the firm posted ($0.48) earnings per share. The firm’s revenue for the quarter was up 37.3% compared to the same quarter last year. On average, equities analysts forecast that Cempra will post ($1.19) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Cempra Inc (CEMP) Lowered to Sell at Vetr Inc.” was published by BBNS and is owned by of BBNS. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://baseballnewssource.com/markets/cempra-inc-cemp-stock-rating-lowered-by-vetr-inc-updated/518068.html.
In related news, Director Dov A. Md Goldstein sold 150,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 8th. The shares were sold at an average price of $3.55, for a total transaction of $532,500.00. Following the sale, the director now owns 95 shares of the company’s stock, valued at approximately $337.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dov A. Md Goldstein sold 105,460 shares of the company’s stock in a transaction that occurred on Friday, January 13th. The stock was sold at an average price of $3.40, for a total transaction of $358,564.00. Following the sale, the director now directly owns 95 shares in the company, valued at approximately $323. The disclosure for this sale can be found here. Corporate insiders own 17.80% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the company. Hodges Capital Management Inc. purchased a new stake in Cempra during the fourth quarter worth $2,800,000. CAM Group Holding A S raised its stake in Cempra by 22.7% in the third quarter. CAM Group Holding A S now owns 896,800 shares of the company’s stock worth $21,703,000 after buying an additional 166,170 shares during the period. Harvey Capital Management Inc. raised its stake in Cempra by 21.7% in the third quarter. Harvey Capital Management Inc. now owns 133,825 shares of the company’s stock worth $3,238,000 after buying an additional 23,875 shares during the period. Bogle Investment Management L P DE bought a new position in Cempra during the fourth quarter worth approximately $280,000. Finally, JPMorgan Chase & Co. boosted its position in Cempra by 43.5% in the third quarter. JPMorgan Chase & Co. now owns 398,622 shares of the company’s stock worth $9,647,000 after buying an additional 120,747 shares in the last quarter. 79.92% of the stock is currently owned by institutional investors and hedge funds.
Cempra, Inc is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Cempra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc and related companies with our FREE daily email newsletter.